| Literature DB >> 20537138 |
Rainer Meierhenrich1, Elisa Steinhilber, Christian Eggermann, Manfred Weiss, Sami Voglic, Daniela Bögelein, Albrecht Gauss, Michael Georgieff, Wolfgang Stahl.
Abstract
INTRODUCTION: Since data regarding new-onset atrial fibrillation (AF) in septic shock patients are scarce, the purpose of the present study was to evaluate the incidence and prognostic impact of new-onset AF in this patient group.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20537138 PMCID: PMC2911754 DOI: 10.1186/cc9057
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Patient characteristics
| New-onset AF, no septic shock | New-onset AF and septic shock | Maintained SR and septic shock | |||
|---|---|---|---|---|---|
| Sex (f/m) | 6/20 | 5/18 | 12/15 | 1.00 | 0.14 |
| Age (years) | 67 (46-84) | 66 (41-85) | 56 (18-80) | 0.59 | < 0.01 |
| History of hypertension | 16 | 17 | 11 | 0.38 | 0.02 |
| Coronary artery disease | 3 | 5 | 2 | 0.45 | 0.23 |
| Heart failure | 0 | 1 | 0 | 0.47 | 0.46 |
| Valvular disease | 0 | 1 | 1 | 0.47 | 1.00 |
| COLD | 4 | 4 | 1 | 1.00 | 0.17 |
| β-blocker | 8 | 8 | 6 | 1.0 | 0.36 |
| digitalis | 0 | 1 | 0 | 0.47 | 0.46 |
| Calcium antagonist | 5 | 7 | 2 | 0.51 | 0.06 |
| ACE inhibitor | 10 | 2 | 7 | 0.02 | 0.15 |
| Lung surgery | 4 | 4 | 2 | - | - |
| Abdominal surgery | 11 | 12 | 19 | - | - |
| Neurosurgery | 4 | 1 | 1 | - | - |
| Traumatologic surgery | 1 | 0 | 2 | - | - |
| Vascular surgery | 1 | 0 | 2 | - | - |
| Aortic surgery | 5 | 4 | 1 | - | - |
| Others | 0 | 2 | 0 | - | - |
Data are given as median (range in parenthesis) or as number. P1-value, patients with new-onset atrial fibrillation (AF) without septic shock vs. septic shock patients with new-onset AF; P2-value, septic shock patients with new-onset AF vs. septic shock patients with maintained sinus rhythm.
ACE, angiotensin-converting enzyme; COLD, chronic obstructive lung disease; f, female; m, male; SR, sinus rhythm.
Severity of illness scores, laboratory tests and use of catecholamines during ICU stay
| New-onset AF, no septic shock | New-onset AF and septic shock | Maintained SR and septic shock | |||
|---|---|---|---|---|---|
| SOFA max | 8.5 (4-14) | 12 (7-17) | 9 (5-18) | < 0.01 | 0.01 |
| SAPS II | 34 (7-60) | 31 (15-63) | 30 (12-65) | 0.87 | 0.12 |
| 249 (14-339) | 288 (72-483) | 273 (23-412) | 0.04 | 0.28 | |
| Noradrenaline max. | 0.18 (0.00-1.00) | 0.50 (0.15-2.00) | 0.30 (0.15-1.40 | < 0.01 | 0.13 |
| Noradrenaline at AF (μg/kg/min) | 0.05 (0.00-0.40) | 0.40 (0.03-1.10) | - | < 0.01 | |
| Dobutamine | 2 | 10 | 6 | < 0.01 | 0.14 |
| K+ (mval/l) | 4.4 (3.9-5.0) | 4.4 (3.8-5.6) | - | 0.63 | |
| Na+ (mval/l) | 137 (130-163) | 140 (132-161) | - | 0.42 | |
| Ca++ (mval/l) | 1.2 (1.1-1.6) | 1.1 (0.7-1.3) | - | 0.10 | |
Data are given as median (range in parenthesis) or number. P1-value, patients with new-onset atrial fibrillation (AF) without septic shock vs. septic shock patients with new-onset AF; P2-value, septic shock patients with new-onset AF vs. septic shock patients with maintained sinus rhythm (SR).
SOFA max, maximum of the daily calculated sequential organ failure assessment score; SAPS II, simplified acute physiologic score II on admission; Max. CRP level, maximal C-reactive protein level during ICU stay; noradrenaline max, maximal noradrenaline dose during ICU stay; noradrenaline at AF, noradrenaline dose when AF occurred; serum electrolytes at AF, serum electrolyte concentrations when AF occurred.
Figure 1Time course of CRP plasma concentrations before, during and after onset of new AF. (a) Patients with new-onset atrial fibrillation (AF) and septic shock. (b) Patients with new-onset AF without septic shock. The median, interquartile range (box), minimum and maximum are shown. Day 0, day of occurrence of AF; Day -3, three days before new-onset of AF; Day 5, five days after occurrence; P1-value, analysis of variance (ANOVA) over time; P2-value, comparison of C-reactive protein (CRP) levels Day 1 versus CRP levels Day -3 (Dunnett's method). (b) Note: P2-value was not calculated for patients with new-onset AF without septic shock as ANOVA did not demonstrate significant change over time.
Patients outcome
| New-onset AF, no septic shock | New-onset AF and septic shock | Maintained SR and septic shock | |||
|---|---|---|---|---|---|
| ICU-mortality | 4 (15%) | 10 (44%) | 6 (22%) | 0.06 | 0.14 |
| 28-day mortality | 4 (15%) | 9 (39%) | 6 (22%) | 0.10 | 0.22 |
| 60-day mortality | 6 (23%) | 11 (48%) | 7 (26%) | 0.08 | 0.14 |
| ICU length of stay, days | 10.5 (2-45) | 30 (9-123) | 17 (4-48) | < 0.001 | 0.017 |
Data are given as number (percentage) or median (range in parenthesis). P1-value, patients with new-onset AF without septic shock versus septic shock patients with new-onset atrial fibrillation (AF); P2-value, septic shock patients with new-onset AF versus septic shock patients with maintained sinus rhythm (SR).
Figure 2ICU mortality. AF, atrial fibrillation; SR, sinus rhythm.
Figure 3Kaplan-Meier survival curves for septic shock patients with new-onset atrial fibrillation and septic shock patients with maintained sinus rhythm. AF, atrial fibrillation; SR, sinus rhythm.
Figure 4ICU length of stay of surviving patients. The median, minimum, maximum and interquartile range (box) are shown. AF, atrial fibrillation; SR, sinus rhythm.